Skip to main content
S&P 5007,720.39-0.30%DOW52,342.56-0.25%NASDAQ26,184.72-1.38%BTC$77,045.00-4.95%ETH$2,215.83-5.85%GOLD$4,026.60-0.12%OIL$102.79+0.77%
Smart Investors Daily
SID Premium
GK

NYSE · GKOS

Glaukos Corporation

Healthcare · Medical - Devices

$242.48

Up+$61.05 (+33.65%)

Updated Oct 30, 2026, 6:11 AM

SID Score

6.5/10

Composite research score

Smart Money

58/100

Neutral

Market cap
6.27B
P/E ratio
-71.17
Dividend yield
0.00%
52-week range
$73.16 – $191.62
Volume
5.42M
Avg. volume
1.14M

Price performance · GKOS

GKOS price history

1M range · 0 trading sessions · Daily adjusted prices

GKOS does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest GKOS news

The latest Smart Investors Daily articles mentioning GKOS.

Stock researchCompany · Overview

GKOS research

Overview

Company profile and research snapshot.

Company profile

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$121.38
Implied upside
—
Analysts
—
GKOS recent ratings
DateFirmRatingTarget
Oct 12, 2026BTIGBuy—
Sep 22, 2026JefferiesBuy—
Aug 20, 2026BTIGBuy—
Jul 30, 2026Wells FargoOverweight—
Jul 30, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 24, 2026

What Glaukos Doubters Missed

Investors who held Glaukos from the start of the year are up 61.6%, including dividends. That headline result lands next to a reminder that fresh Epioxa data, a new retinal licensing deal and record 2026 guidance all arrived only after the clock started. If you were deciding on 1 January whether to buy, what weight would you have put on early regulatory wins and high expected P/E multiples, compared with concentration and reimbursement risk? This theme extends beyond Glaukos. See which of 34...

Yahoo · Oct 23, 2026

How Investors May Respond To Glaukos (GKOS) Positive Trial Results

Glaukos reported positive topline Phase 4 data for iDose TR used during cataract surgery in open-angle glaucoma and ocular hypertension, with the implant achieving statistically significant reductions in mean diurnal intraocular pressure versus cataract surgery alone at three months. The 3.6 mmHg incremental intraocular pressure improvement from adding iDose TR to cataract surgery highlights how Glaukos is pushing toward more interventional, procedure-based glaucoma care rather than reliance...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By